146 related articles for article (PubMed ID: 18616938)
1. Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia.
Didier C; Cavelier C; Quaranta M; Demur C; Ducommun B
Eur J Pharmacol; 2008 Sep; 591(1-3):102-5. PubMed ID: 18616938
[TBL] [Abstract][Full Text] [Related]
2. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.
Ikezoe T; Yang J; Nishioka C; Takezaki Y; Tasaka T; Togitani K; Koeffler HP; Yokoyama A
Leukemia; 2009 Sep; 23(9):1564-76. PubMed ID: 19421227
[TBL] [Abstract][Full Text] [Related]
3. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
Gilmartin AG; Bleam MR; Richter MC; Erskine SG; Kruger RG; Madden L; Hassler DF; Smith GK; Gontarek RR; Courtney MP; Sutton D; Diamond MA; Jackson JR; Laquerre SG
Cancer Res; 2009 Sep; 69(17):6969-77. PubMed ID: 19690138
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
[TBL] [Abstract][Full Text] [Related]
5. Promotion of mitosis by activated protein kinase B after DNA damage involves polo-like kinase 1 and checkpoint protein CHFR.
Shtivelman E
Mol Cancer Res; 2003 Nov; 1(13):959-69. PubMed ID: 14638868
[TBL] [Abstract][Full Text] [Related]
6. G2/M checkpoint stringency is a key parameter in the sensitivity of AML cells to genotoxic stress.
Didier C; Cavelier C; Quaranta M; Galcera MO; Demur C; Laurent G; Manenti S; Ducommun B
Oncogene; 2008 Jun; 27(27):3811-20. PubMed ID: 18212737
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
Münch C; Dragoi D; Frey AV; Thurig K; Lübbert M; Wäsch R; Bogatyreva L; Hauschke D; Lassmann S; Werner M; May AM
Leuk Res; 2015 Apr; 39(4):462-70. PubMed ID: 25697066
[TBL] [Abstract][Full Text] [Related]
8. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
Shin SB; Woo SU; Yim H
J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
[TBL] [Abstract][Full Text] [Related]
9. Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 up-regulation and PLK1 down-regulation.
Ismail IA; Kang KS; Lee HA; Kim JW; Sohn YK
Eur J Pharmacol; 2007 Dec; 575(1-3):12-20. PubMed ID: 17706963
[TBL] [Abstract][Full Text] [Related]
10. Getting in and out of mitosis with Polo-like kinase-1.
van Vugt MA; Medema RH
Oncogene; 2005 Apr; 24(17):2844-59. PubMed ID: 15838519
[TBL] [Abstract][Full Text] [Related]
11. Polo-like kinase 1 inactivation following mitotic DNA damaging treatments is independent of ataxia telangiectasia mutated kinase.
Yuan JH; Feng Y; Fisher RH; Maloid S; Longo DL; Ferris DK
Mol Cancer Res; 2004 Jul; 2(7):417-26. PubMed ID: 15280449
[TBL] [Abstract][Full Text] [Related]
12. A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.
Müller-Tidow C; Bug G; Lübbert M; Krämer A; Krauter J; Valent P; Nachbaur D; Berdel WE; Ottmann OG; Fritsch H; Munzert G; Garin-Chesa P; Fleischer F; Taube T; Döhner H
Br J Haematol; 2013 Oct; 163(2):214-22. PubMed ID: 24033250
[TBL] [Abstract][Full Text] [Related]
13. Targeting Polo-like kinase in cancer therapy.
Degenhardt Y; Lampkin T
Clin Cancer Res; 2010 Jan; 16(2):384-9. PubMed ID: 20068088
[TBL] [Abstract][Full Text] [Related]
14. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Nihal M; Stutz N; Schmit T; Ahmad N; Wood GS
Cell Cycle; 2011 Apr; 10(8):1303-11. PubMed ID: 21436619
[TBL] [Abstract][Full Text] [Related]
15. Polo-like kinases in AML.
Berg T; Bug G; Ottmann OG; Strebhardt K
Expert Opin Investig Drugs; 2012 Aug; 21(8):1069-74. PubMed ID: 22667760
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of human ABCB1 in cancer cells leads to reduced activity of GSK461364, a specific inhibitor of polo-like kinase 1.
Wu CP; Hsiao SH; Luo SY; Tuo WC; Su CY; Li YQ; Huang YH; Hsieh CH
Mol Pharm; 2014 Oct; 11(10):3727-36. PubMed ID: 25192198
[TBL] [Abstract][Full Text] [Related]
17. Regulation of Polo-like kinase 1 by DNA damage in mitosis. Inhibition of mitotic PLK-1 by protein phosphatase 2A.
Jang YJ; Ji JH; Choi YC; Ryu CJ; Ko SY
J Biol Chem; 2007 Jan; 282(4):2473-82. PubMed ID: 17121863
[TBL] [Abstract][Full Text] [Related]
18. Polo and Aurora kinases: lessons derived from chemical biology.
Taylor S; Peters JM
Curr Opin Cell Biol; 2008 Feb; 20(1):77-84. PubMed ID: 18249108
[TBL] [Abstract][Full Text] [Related]
19. A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt's lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis.
Ergul M; Bakar-Ates F
Chem Biol Interact; 2020 Dec; 332():109288. PubMed ID: 33075310
[TBL] [Abstract][Full Text] [Related]
20. ATM/ATR-related checkpoint signals mediate arsenite-induced G2/M arrest in primary aortic endothelial cells.
Tsou TC; Tsai FY; Yeh SC; Chang LW
Arch Toxicol; 2006 Dec; 80(12):804-10. PubMed ID: 16645841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
